Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...

In a recent publication of the acute myeloid leukemia (AML) arm of the Tumor Profiler, researchers demonstrated that multi-OMICS profiles can be generated in a clinically meaningful turnaround time ...

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...

As word of his diagnosis spread, friends, neighbors, and even strangers wanted to help. A small committee of friends and ...

Autolus Therapeutics said it received Food and Drug Administration approval of its treatment of acute lymphoblastic leukemia, or ALL, an aggressive blood and bone marrow cancer, for certain patients.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...